(NASDAQ: SUPN) Supernus Pharmaceuticals's forecast annual revenue growth rate of 3.7% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 9.16%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.16%.
Supernus Pharmaceuticals's revenue in 2024 is $607,521,000.On average, 3 Wall Street analysts forecast SUPN's revenue for 2024 to be $32,947,706,764, with the lowest SUPN revenue forecast at $32,518,037,360, and the highest SUPN revenue forecast at $33,380,112,917. On average, 3 Wall Street analysts forecast SUPN's revenue for 2025 to be $33,366,757,587, with the lowest SUPN revenue forecast at $31,856,839,091, and the highest SUPN revenue forecast at $36,218,120,385.
In 2026, SUPN is forecast to generate $37,739,916,367 in revenue, with the lowest revenue forecast at $36,004,654,057 and the highest revenue forecast at $40,711,860,273.